Show simple item record

dc.contributor.authorYoung, Caitlin
dc.contributor.authorPhillips, Rhiannon
dc.contributor.authorEbenezer, Louise
dc.contributor.authorZutt, Rodi
dc.contributor.authorPeall, Kathryn
dc.date.accessioned2020-02-13T10:45:28Z
dc.date.available2020-02-13T10:45:28Z
dc.date.issued2020-02-28
dc.identifier.citationYoung, C., Phillips, R., Ebenezer, L., Zutt, R. and Peall, K.J., (2020) 'Management of Parkinson's Disease during pregnancy: literature review and multi‐disciplinary input', Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.12925
dc.identifier.issn2330-1619
dc.identifier.urihttp://hdl.handle.net/10369/10928
dc.descriptionArticle published in Movement Disorders Clinical Practice available at https://doi.org/10.1002/mdc3.12925en_US
dc.description.abstractBackground There are no standardised clinical guidelines for the management of Parkinson’s disease during pregnancy. Increasing maternal age would suggest that the incidence of pregnancy in women diagnosed with Parkinson’s disease is likely to increase. Objective To evaluate the evidence for the treatment of Parkinson’s disease during pregnancy, and to canvass opinion from patients and clinical teams as to the optimum clinical management in this setting. Methods This involved: i) a literature review of available evidence for the use of oral medical therapy for the management of PD during pregnancy, and ii) anonymised survey of patients and clinical teams relating to previous clinical experiences. Results Literature review identified 31 publications (148 pregnancies; 49 Parkinson’s Disease, 2 Parkinsonism, 21 Dopa-Responsive Dystonia, 32 Restless Leg Syndrome, 1 Schizophrenia and 43 unknown indication) detailing treatment with levodopa, and 12 publications with dopamine agonists. Adverse outcomes included seizures and congenital malformations. Survey participation included patients (n=7), neurologists (n=35), PD Nurse Specialists (n=50), obstetricians (n=15) and midwives (n=20) and identified a further 34 cases of pregnancy in women with PD. Common themes for suggested management included: optimisation of motor symptoms, preference for levodopa monotherapy, and normal delivery unless indicated by obstetric causes. Conclusions This study demonstrates the paucity of evidence for decision-making in the medical management of PD during pregnancy. Collaboration is needed to develop a prospective registry, with longitudinal maternal and child health outcome measures, to facilitate consensus management guidelines.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofseriesMovement Disorders Clinical Practice;
dc.subjectmovement disordersen_US
dc.subjectParkinson’s Diseaseen_US
dc.titleManagement of Parkinson’s Disease during pregnancy: Literature review and multi-disciplinary inputen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1002/mdc3.12925
dcterms.dateAccepted2020-02-08
rioxxterms.funderCardiff Metropolitan Universityen_US
rioxxterms.identifier.projectCardiff Metropolian (Internal)en_US
rioxxterms.versionAMen_US
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
rioxxterms.freetoread.startdate2021-02-28
rioxxterms.funder.project37baf166-7129-4cd4-b6a1-507454d1372een_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record